Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29992297 | 0.91 | KMT2A (0.51) | MDM4TP53KMT2APTPN1CASP3 | |
| SCHEMBL17826038 | 0.91 | KMT2A (0.51) | MDM4TP53KMT2APTPN1CASP3 | |
| SCHEMBL31537233 | 0.89 | MDM4 (0.46) | MDM4TP53PTPN1CASP3TLR2 | |
| SCHEMBL17751704 | 0.87 | MDM4 (0.43) | MDM4TP53PTPN1CASP3TLR2 | |
| SCHEMBL26474537 | 0.85 | MDM2 (0.46) | MDM4TP53TLR2MDM2 | |
| SCHEMBL17751673 | 0.84 | TLR2 (0.46) | MDM4TP53TLR2MDM2 | |
| SCHEMBL31591662 | 0.84 | MDM2 (0.42) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL13049087 | 0.84 | TLR2 (0.47) | MDM4TP53KMT2ATLR2MDM2 | |
| SCHEMBL31624497 | 0.84 | HDAC1 (0.48) | KMT2ATLR2 | |
| SCHEMBL31624368 | 0.84 | HDAC1 (0.48) | KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171516-A1 | PEPTIDE ACIDS AS A GLP1R AGONIST AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171516-A1 | PEPTIDE ACIDS AS A GLP1R AGONIST AND ANTIBODY-DRUG CONJUGATES THEREOF | GLP1R, GIPR, GCGR | MDM4 4740/4885TP53 3214/4885KMT2A 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.